Goldman Sachs analyst David Roman lowered the firm’s price target on Teladoc (TDOC) to $9 from $10 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc price target lowered to $7.50 from $8 at BofA
- Teladoc call volume above normal and directionally bullish
- Balancing Emerging Strengths and Persistent Headwinds: Maintaining a Hold on Teladoc Amid Mixed Growth Signals and Limited Near-Term Upside
- Teladoc Board Member J. Eric Evans to Retire
- Teladoc Amends Incentive Plan to Increase Shares